Application

Anti-NG2, clone 1L2 ZooMAb, Cat. No. ZRB5320, is a recombinant Rabbit Monoclonal Antibody that specifically targets Chondroitin sulfate proteoglycan 4 (NG2) and has been tested for use in Immunocytochemistry, Immunofluorescence, and Western Blotting.

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected NG2 in C6 cells.Immunofluorescence Analysis: A 1:100 dilution representative lot detected NG2 in rat brain tissue sections.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.

Immunogen

Recombinant extracellular domain of rat Chondroitin sulfate proteoglycan 4 (NG2).

Legal Information

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Physical form

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitution

120 µg/mL after reconstitution at 25 µL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Specificity

Clone 1L2 is a ZooMab rabbit recombinant monoclonal antibody that specifically detects Chondroitin sulfate proteoglycan 4 (NG2).

Storage and Stability

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

Target description

Chondroitin sulfate proteoglycan 4 (UniProt: Q00657; also known as Chondroitin sulfate proteoglycan NG2, HSN tumor-specific antigen) is encoded by the Cspg4 (also known as Ng2) gene (Gene ID: 81651) in rat. Chondroitin sulfate proteoglycan NG2 is a single-pass type I membrane protein that plays a role in cell proliferation and migration and stimulates endothelial cells motility during microvascular morphogenesis. It is present in neural cells and in extraneural tissues, especially in the developing mesenchyme. Its level of expression is highest on immature, proliferating cells and decreases when these cells begin to differentiate. It is found on the surfaces of an unusual class of glial cells within the developing and mature central nervous system that have the properties of oligodendrocyte precursor cells. It is a major chondroitin sulfate proteoglycan that is produced after spinal cord injury and is expressed by macrophages and oligodendrocyte progenitors. It is also reported to inhibit neurite outgrowth and growth cone collapse during axon regeneration. NG2 chondroitin sulfate proteoglycan is synthesized with a signal peptide (aa 1-29), which is subsequently cleaved off in the mature form. This ZooMAb recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Jones, LL et al. (2002). J. Neurosci. 22(7):2792-2803).